Stock Events

Stock Events

AIM ImmunoTech 

$0.23
56
-$0-0.13% Today

Statistics

Day High
0.24
Day Low
0.23
52W High
2.88
52W Low
0.09
Volume
25,725,374
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
115.98%
Dividend
0.27

Upcoming

14
NOV
Dividend Ex
Estimated
 
14
MAY 27
Dividend Ex
Estimated
 

Dividends

115.98%Dividend Yield
May 26
$0.27
Nov 25
$0.27
May 25
$0.27
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

18AugExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-8
-5.35
-2.71
-0.06
Expected EPS
-0.295
Actual EPS
N/A

Financials

-10,188.24%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
340,000Revenue
-34.64MNet Income

Analyst Ratings

10Average Price Target
The highest estimate is 10.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow AIM. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Incyte
INCY
Mkt Cap19.41B
Incyte Corporation operates in the biopharmaceutical field focusing on the discovery, development, and commercialization of proprietary therapeutics, including those that affect the immune system's function, which competes with AIM's immunotherapy approaches.
Gilead Sciences
GILD
Mkt Cap166.82B
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops, and commercializes innovative medicines in areas of unmet medical need, including treatments that modulate the immune system, directly competing with AIM's product pipeline.
Moderna
MRNA
Mkt Cap18.6B
Moderna, Inc. focuses on mRNA-based therapies, some of which are designed to activate the immune system against cancer and infectious diseases, competing with AIM's immunotherapeutic strategies.
BioNTech
BNTX
Mkt Cap23.3B
BioNTech SE operates in the field of mRNA technology and immunotherapy, developing treatments that stimulate the body's immune response, similar to AIM's focus, making them direct competitors in the immunotherapy space.
Novavax
NVAX
Mkt Cap1.51B
Novavax, Inc. is involved in the development of vaccines that stimulate the immune system, competing with AIM ImmunoTech's efforts in immune system modulation for disease prevention and treatment.
Regeneron Pharmaceuticals
REGN
Mkt Cap66.98B
Regeneron Pharmaceuticals, Inc. is known for its innovation in biotechnology, including the development of immune-modulating drugs, which places it in direct competition with AIM in the field of immunotherapies.
Cytodyn
CYDY
Mkt Cap464.45M
CytoDyn Inc. focuses on the development and commercialization of novel therapeutics for the treatment of immune, viral, and other serious diseases, competing with AIM's focus on immune-based therapies.
iBio
IBIO
Mkt Cap91.41M
iBio, Inc. is a biotechnology company that focuses on developing plant-based biopharmaceuticals, including vaccines and therapeutic proteins that modulate the immune system, making it a competitor to AIM in the broader field of immune-based therapies.

About

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. The company is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.
Show more...
CEO
Mr. Thomas K. Equels Esq., J.D., M.S.
Employees
21
Country
United States
ISIN
US00901B3033

Listings

LSE
GB
0A4Y.LSE
F
DE
HXB.F
MU
DE
HXB.MU
STU
DE
HXB.STU

0 Comments

Share your thoughts

FAQ

What is AIM ImmunoTech stock price today?▼
The current price of AIM is $0.23 USD — it has decreased by -0.13% in the past 24 hours. Watch AIM ImmunoTech stock price performance more closely on the chart.
What is AIM ImmunoTech stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange AIM ImmunoTech stocks are traded under the ticker AIM.
When is the next AIM ImmunoTech earnings date?▼
AIM ImmunoTech is going to release the next earnings report on August 18, 2026.
What were AIM ImmunoTech earnings last quarter?▼
AIM earnings for the last quarter are -0.69 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
What is AIM ImmunoTech revenue for the last year?▼
AIM ImmunoTech revenue for the last year amounts to 340,000 USD.
What is AIM ImmunoTech net income for the last year?▼
AIM net income for the last year is -34.64M USD.
Does AIM ImmunoTech pay dividends?▼
Yes, AIM dividends are paid semi-annual. The last dividend per share was 0.27 USD. As of today, Dividend Yield (FWD)% is 115.98%.
How many employees does AIM ImmunoTech have?▼
As of May 26, 2026, the company has 21 employees.
In which sector is AIM ImmunoTech located?▼
AIM ImmunoTech operates in the Health & Wellness sector.
When did AIM ImmunoTech complete a stock split?▼
The last stock split for AIM ImmunoTech was on January 09, 2026 with a ratio of 1001:1000.
Where is AIM ImmunoTech headquartered?▼
AIM ImmunoTech is headquartered in Ocala, United States.